Experimental Ebola drugs are being shipped to Democratic Republic of Congo as the United States releases doses of a treatment for clinical trials in a widening outbreak that has caused more than 1,000 cases and over 250 deaths, the World Health Organization and US officials have said.
The US Department of Health and Human Services confirmed it will provide doses of MBP134, an antibody drug developed by California-based Mapp Biopharmaceutical, for compassionate use in the DRC and to support a clinical trial in the outbreak region.